open access

Vol 10, No 3 (2014)
Review paper
Published online: 2014-07-30
Get Citation

Pancreatic cancer — the role of systemic and combined modality treatment

Joanna Kubicka-Wołkowska, Rafał Czyżykowski, Sylwia Dębska-Szmich, Maja Lisik-Habib, Piotr Potemski
Onkol. Prak. Klin 2014;10(3):152-159.

open access

Vol 10, No 3 (2014)
REVIEW ARTICLES
Published online: 2014-07-30

Abstract

Pancreatic cancer (PC) prognosis is extremely poor. Mortality and incidence rates for this malignant neoplasm reach almost equal values and a 5-year survival rate does not exceed 5%. This is mainly due to the fact that more than 50% of patients present distant metastases at diagnosis and up to 80% of patients after radical surgery, which is the only potentially curative method, experience recurrence within 2 years. Gemcitabine or fluorouracil are now considered the standard of care in the adjuvant setting as such treatment prolongs survival, whereas in palliative therapy gemcitabine or in selected patients FOLFIRINOX are recommended. Optimal management of locally advanced PC remains controversial. In order to improve percentage of radical resections attempts are made to apply neoadjuvant treatment by using chemo- or chemoradiotherapy. However, there are no evidence that such a strategy is associated with improvement in overall survival.

Despite constant searching for new, more effective therapies of PC, results of treatment remain unsatisfactory. For majority of patients, due to advanced disease at diagnosis, palliative chemotherapy remains the only treatment option.

Abstract

Pancreatic cancer (PC) prognosis is extremely poor. Mortality and incidence rates for this malignant neoplasm reach almost equal values and a 5-year survival rate does not exceed 5%. This is mainly due to the fact that more than 50% of patients present distant metastases at diagnosis and up to 80% of patients after radical surgery, which is the only potentially curative method, experience recurrence within 2 years. Gemcitabine or fluorouracil are now considered the standard of care in the adjuvant setting as such treatment prolongs survival, whereas in palliative therapy gemcitabine or in selected patients FOLFIRINOX are recommended. Optimal management of locally advanced PC remains controversial. In order to improve percentage of radical resections attempts are made to apply neoadjuvant treatment by using chemo- or chemoradiotherapy. However, there are no evidence that such a strategy is associated with improvement in overall survival.

Despite constant searching for new, more effective therapies of PC, results of treatment remain unsatisfactory. For majority of patients, due to advanced disease at diagnosis, palliative chemotherapy remains the only treatment option.

Get Citation

Keywords

pancreatic cancer, chemotherapy, chemoradiotherapy, neoadjuvant treatment, adjuvant treatment, palliative chemotherapy, gemcitabine, fluorouracil

About this article
Title

Pancreatic cancer — the role of systemic and combined modality treatment

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 3 (2014)

Article type

Review paper

Pages

152-159

Published online

2014-07-30

Bibliographic record

Onkol. Prak. Klin 2014;10(3):152-159.

Keywords

pancreatic cancer
chemotherapy
chemoradiotherapy
neoadjuvant treatment
adjuvant treatment
palliative chemotherapy
gemcitabine
fluorouracil

Authors

Joanna Kubicka-Wołkowska
Rafał Czyżykowski
Sylwia Dębska-Szmich
Maja Lisik-Habib
Piotr Potemski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl